Biomind Begins Clinical Trial For Inhaled DMT Analog Substance To Treat Depression
Biomind Labs (OTCQB:BMNDF) has begun administering its proprietary second-generation psychedelic, BMND01, in a Phase 1/2a clinical trial for treatment-resistant depression (TRD).
